VEGFB是阿尔茨海默病的潜在治疗标:综合性多omics分析的见解
Hongyu Ye1, Caixiang Zhuang2,3, Ziyang Jin2
1Department of Neurology, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, China.
Journal of Alzheimer's disease : JAD
|October 17, 2025
概括
这项研究确定了血管内皮生长因子B (VEGFB) 作为阿尔茨海默病 (AD) 的有希望的治疗点. 调节VEGFB及其通路可能为AD患者提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前的阿尔茨海默病 (AD) 治疗疗法有效性有限.
- 对于阿尔茨海默病的新型疾病修饰疗法有极大需求.
研究的目的:
- 确定改善阿尔茨海默病预后的新型治疗点.
- 探索血管内皮生长因子B (VEGFB) 作为AD治疗点的潜力.
主要方法:
- 对脑组织转录组数据集的元分析,以识别AD中差异表达基因 (DEGs).
- 门德尔随机化 (MR) 和基于摘要的MR (SMR) 分析以选AD药物标.
- 局部化,基因组丰富分析 (GSEA),蛋白质-蛋白质相互作用 (PPI) 网络,药物预测和分子对接来推断机制.
主要成果:
- 从12个大脑组织数据集中确定了262种可药物治疗的AD相关的DEG.
- VEGFB被确定为一个重要的标,显示较低的DNA甲基化,更高的基因表达和AD风险增加之间的相关性.
- 通过多种分析方法,VEGFB证明了AD的治疗潜力.
结论:
- 调节VEGFB及其相关途径为阿尔茨海默病提供了一个有前途的治疗策略.
- VEGFB代表了未来药物开发和针对AD的向治疗的新方向.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.门德尔的随机化VEGFBB VEGFBB VEGFBB VEGFBB VEGFBB VEGFBB VEGFBB VEGFBB VEGFBB VEGFBB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB VEGFB毒品目标是毒品的目标.更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.3K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.7K
相关概念视频
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K